Literature DB >> 15728465

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Paul A Antony1, Ciriaco A Piccirillo, Akgül Akpinarli, Steven E Finkelstein, Paul J Speiss, Deborah R Surman, Douglas C Palmer, Chi-Chao Chan, Christopher A Klebanoff, Willem W Overwijk, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

CD4(+) T cells control the effector function, memory, and maintenance of CD8(+) T cells. Paradoxically, we found that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cells directed against a persisting tumor/self-Ag. However, adoptive transfer of CD4(+)CD25(-) Th cells (Th cells) with tumor/self-reactive CD8(+) T cells and vaccination into CD4(+) T cell-deficient hosts induced autoimmunity and regression of established melanoma. Transfer of CD4(+) T cells that contained a mixture of Th and CD4(+)CD25(+) T regulatory cells (T(reg) cells) or T(reg) cells alone prevented effective adoptive immunotherapy. Maintenance of CD8(+) T cell numbers and function was dependent on Th cells that were capable of IL-2 production because therapy failed when Th cells were derived from IL-2(-/-) mice. These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728465      PMCID: PMC1403291          DOI: 10.4049/jimmunol.174.5.2591

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.

Authors:  P Shrikant; A Khoruts; M F Mescher
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

2.  Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.

Authors:  A L Marzo; B F Kinnear; R A Lake; J J Frelinger; E J Collins; B W Robinson; B Scott
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

3.  CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells.

Authors:  L Cederbom; H Hall; F Ivars
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

4.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.

Authors:  M Itoh; T Takahashi; N Sakaguchi; Y Kuniyasu; J Shimizu; F Otsuka; S Sakaguchi
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

5.  CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion.

Authors:  Maria A Curotto de Lafaille; Andreia C Lino; Nino Kutchukhidze; Juan J Lafaille
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

Review 6.  The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.

Authors:  R F Wang
Journal:  Trends Immunol       Date:  2001-05       Impact factor: 16.687

7.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

8.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Authors:  H L Hanson; D L Donermeyer; H Ikeda; J M White; V Shankaran; L J Old; H Shiku; R D Schreiber; P M Allen
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

9.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

Authors:  W W Overwijk; D S Lee; D R Surman; K R Irvine; C E Touloukian; C C Chan; M W Carroll; B Moss; S A Rosenberg; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  304 in total

1.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

Review 3.  Therapeutic cancer vaccines: are we there yet?

Authors:  Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Authors:  Akio Ohta; J Kjaergaard; S Sharma; M Mohsin; N Goel; M Madasu; E Fradkov; Akiko Ohta; M Sitkovsky
Journal:  Br J Pharmacol       Date:  2008-12-09       Impact factor: 8.739

6.  Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Authors:  Michael Y Gerner; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

8.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone.

Authors:  Jeffrey S Miller; Daniel J Weisdorf; Linda J Burns; Arne Slungaard; John E Wagner; Michael R Verneris; Sarah Cooley; Rosanna Wangen; Susan K Fautsch; Roby Nicklow; Todd Defor; Bruce R Blazar
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

9.  Regulatory T cells in renal disease.

Authors:  Yuan Min Wang; Min Hu; Ya Wang; Tania Polhill; Geoff Yu Zhang; Yiping Wang; Vincent W S Lee; David C H Harris; Stephen I Alexander
Journal:  Int J Clin Exp Med       Date:  2008-08-20

Review 10.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.